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In the past decade cancer research has recognized the importance of tumorstroma interactions for the progression of primary
tumors to an aggressive and invasive phenotype and for colonization of new organs in the context of metastasis. The dialogue
between tumor cells and the surrounding stroma is a complex and dynamic phenomenon, as many cell types and soluble factors
areinvolved.Whilethefunctionofmanyoftheplayersinvolvedinthiscrosstalkhavebeenstudied,theregulatorymechanismsand
signaling pathways that control their expression haven’t been investigated in depth. By using a novel, interdisciplinary approach
applied to the mechanism of action of the metastasis suppressor, Raf kinase inhibitory protein (RKIP), we identiﬁed a signaling
pathway that suppresses invasion and metastasis through regulation of stroma-associated genes. Conceptually, the approach we
developed uses a master regulator and expression arrays from breast cancer patients to formulate hypotheses based on clinical
data. Experimental validation is followed by further bioinformatic analysis to establish the clinical signiﬁcance of discoveries.
Using RKIP as an example we show here that this multi-step approach can be used to identify gene regulatory mechanisms that
aﬀect tumor-stroma interactions that in turn inﬂuence metastasis to the bone or other organs.
1.Introduction
Under normal physiological conditions, the stromal com-
partment of epithelial tissue regulates homeostasis by main-
taining the proper architecture and nutrient levels required
for epithelial function. It also serves as an important barrier
to cell transformation. However in response to lesions (i.e.,
wounding) the stromal compartment undergoes changes
including the recruitment and activation of ﬁbroblasts,
immune, and endothelial cells that in turn provide growth,
andmatrixremodeling factors,aswellasanewbloodsupply.
Similar changes in the stromal compartment have been
shown to occur during tumor growth and the importance
of the stromal compartment, called “the tumor microen-
vironment,” in modulating and driving cancer progression
has become increasingly evident [1]. The tumor microen-
vironment has become the subject of intense therapeutic
and prognostic interest as its phenotypic and molecular
characteristicshavebeencorrelatedwithdisease-freesurvival
in multiple tumor types [2].
It is believed that during the ﬁrst phase of carcinogenesis
the tumor microenvironment initially reacts to suppress ma-
lignant transformation by maintaining tissue architecture
and diﬀerentiation. As cancer progresses, however, the local
stromal compartmentshifts to an activated, growth-promot-
ing state, in many ways similar to an inﬂammatory state,
which is initiated and maintained by continuous paracrine
communication between stromal and tumor cells. Stromal
components engage in a dynamic signaling circuit with pri-
mary tumor cells and coevolve with tumor cells to promote
tumor progression to an invasive phenotype [3]. Various
stromal components, including vascular cells, pericytes, ﬁb-
roblasts, inﬂammatory cells, and extracellular matrix com-
ponents participate in this cycle [4, 5]. A large number of
activated myoﬁbroblasts, characterized by the expression of2 International Journal of Breast Cancer
α-smooth muscle actin (α-SMA), are frequently found in
the stroma of human breast carcinoma and are referred
to as carcinoma-associated ﬁbroblasts (CAFs). The precise
cellular origin of these activated myoﬁbroblasts is not clear
but it has been shown that when inoculated with carcinoma
cells, CAFs can promote tumor growth in mouse xenograft
models [6]. CAFs secrete high levels of stromal cell-derived
factor-1 (SDF-1 or CXCL12), a chemokine that can activate
its cognate receptor, CXCR4, which is expressed by many
carcinoma cells, and stimulate their proliferation. On the
other hand SDF-1 can mediate recruitment of endothelial
progenitor cells thus promoting angiogenesis, and it has also
beenimplicatedinanautocrinesignalingloopthatpromotes
diﬀerentiation of normal stromal ﬁbroblasts into myoﬁb-
roblasts [7].
A number of other cytokines, chemokines, and growth
factors secreted by cancer cells themselves or by tumor-as-
sociated stromal cells have been shown to sustain tumor
cell proliferation and progression through diﬀerent mech-
anisms. The list of these autocrine/paracrine factors is
constantly growing and includes vascular endothelial growth
factor (VEGF), ﬁbroblast growth factor (FGF), transforming
growth factor-β (TGF-β), hepatocyte growth factor (HGF),
interleukin-6 (IL-6), and osteopontin (OPN) [8]. An impor-
tant component of this signaling loop is the recruitment and
activation of bone marrow-derived myeloid cells (BMDCs),
including macrophages, monocytes, mast cells, and neu-
trophilis. BMDCs have been shown to play a major role in
the development and growth of the primary tumor and also
in the subsequent hematological dissemination [9]. BMDCs
can in fact contribute to the induction of angiogenesis by
activatingendothelialcellsandarerecognizedasmajordeter-
minants of tumor invasion. Secretion of diﬀerent classes of
proteases (matrix metalloproteinases, cathepsins, and serine
proteases),producedbystromaland/ortumorcells,hasbeen
shown to facilitate cancer cell migration by disrupting cell-
cell junctions and promoting invasion of the surrounding
tissues by proteolytic degradation of the extracellular matrix
(ECM) and the basement membrane.
Metastasisistheprimarycauseofmortalityinbreastcan-
cer patients and can emerge many years after the removal of
the primary tumor. Metastastic progression is a complicated
multistepprocesswhichincludesatleastthreediscretestages:
(1) epithelial-mesenchymal transition (EMT) leading to
migration,invasion,andintravasation;(2)circulation,trans-
portation, and extravasation of cells, which then undergo
mesenchymal-epithelial transition (MET); (3) colonization
of tumor cells within distal tissues including bone and
lung [10]. The eﬃciency of each of these steps on the way
to metastasis is highly aﬀected by interactions with a dis-
tinct local microenvironment. Cancer cells interact with an
activated stroma during the initial phases of invasion and in-
travasation, with the bloodstream during hematological dis-
semination,andﬁnallywiththemetastaticsitesduringextra-
vasationandcolonization.Itisgenerallybelievedthateachof
thesestagesishighlyineﬃcient,and,inparticular,onlyavery
small percentage of the tumor cells that enter the circulatory
system are able to colonize and form a tumor at distal sites.
This concept highlights the fact that healthy tissues exert
aprotectivefunctiontowardinvadingcancercellsandensure
thatorderis preservedwithinthe tissue throughhomeostatic
mechanisms.Cancercellsthatescapethisprotectivefunction
and are able to modify the surrounding stroma to their own
advantage are the ones that will eventually succeed in colon-
izing new organs.
Many studies have highlighted the concept of tissue
tropism: although the blood ﬂow pattern certainly con-
tributes to preferred metastatic sites of speciﬁc carcinomas,
the complex molecular mechanism of homing metastatic
cells is also determined by interactions with the microenvi-
r o n m e n ta tt a r g e to r g a n s .An u m b e ro fm o l e c u l a rm e d i a t o r s
of this interaction have been revealed by recent publications,
and gene expression proﬁling studies have generated distinct
gene expression signatures for organ-speciﬁc metastatic
variants [10–13]. A major role in the tropism of metastatic
cells to diﬀerent organs is exerted by chemokines and their
cognate receptors [14]. Local expression in target tissues is
believed to guide metastatic cells to speciﬁc destinations as
a result of local chemotaxis in combination with induction
of invasive properties. As a homing mechanism, metastatic
breast cancer cells speciﬁcally express functional CXCR4 and
CCR7 receptors that induce actin polymerization, formation
of pseudopodia, and chemotaxis for directional migration
[14]. Interestingly, their respective ligands SDF-1 and CCL21
are mainly distributed in organs that represent the main site
of breast cancer metastasis, in particular bone.
Breast cancers metastasize to lung, liver, bone, and brain.
Bone metastasis is very common among late-stage breast
cancer patients but current treatment methods for bone
metastasis are mainly palliative, and more eﬀective disease-
modifying therapies are needed. Breast cancer frequently
generates osteolytic bone metastasis by secreting a series of
growth factors that inﬂuence bone matrix and bone stromal
cells, tipping the balance to osteolytic bone destruction. In
thiscontexttumor-derivedfactorsincludeangiogenicfactors
(FGFandVEGF),mediatorsofimmune cellrecruitmentand
activation (TGFβ and TNFα), and mediators of ﬁbroblasts
activation (FGF and TGFβ). Moreover cancer cells promote
bone degradation by direct secretion of metalloproteinases
(suchasMMP1)andcollagenaseIorthroughindirectmech-
anisms by activating osteoclasts. Other tumor-derived cytok-
ines and cell surface/ECM proteins like bone morphogenetic
protein (BMP), interleukin-11 (IL-11), osteopontin (OPN),
and endothelin-1 participate and feed this vicious cycle.
In this scenario bone reabsorption by osteoclasts releases
a number of growth factors embedded in the bone matrix
includinginsulin-likegrowthfactors(IGFs),TGF-β,platelet-
derived growth factor (PDGF), and BMP which become part
of this signaling circuit that push osteolytic lesions.
Gene expression proﬁling of a bone-tropic subpopula-
tion of the breast cancer cell line MDA-MB-231 has revealed
a “bone metastasis signature” (BMS) [11]. As expected, the
most highly overexpressed genes in the BMS encode mostly
cell surface and secreted proteins that alter the bone micro-
environment in order to facilitate growth of metastases and
formation of osteolytic bone lesions as described above. The
BMS includes OPN, connective tissue growth factor(CTGF),
ﬁbroblast growth factor 5 (FGF5), the osteoclast-activatingInternational Journal of Breast Cancer 3
cytokine IL-11, CXCR4, and MMP1 as well as many other
genes. Expression of these genes in the primary tumor has
multiple functions including: (i) targeting cells speciﬁcally
to the bone microenvironment via homing factor CXCR4;
(ii) facilitating colonization of the bone via expression
of bone extracellular matrix degrading enzymes (MMP1,
ADAMTS1); (iii) activating osteoclasts and favoring adhe-
sion to the bone surface through OPN [15]. Overexpression
of individual genes in the signature led to only a marginal
increaseinbonemetastasis,whereascoexpressionofmultiple
genes dramatically increases both the rate and incidence of
bone metastasis [11]. This concept implies that these genes
cooperate to push the metastatic phenotype and may not be
highly eﬀective if isolated from their signaling context. This
observation also highlights the importance of understanding
the master molecular mechanisms that regulate expression
of genes in order to develop target therapies that aﬀect their
combined expression rather than an isolated component.
2.RKIP Deﬁnes WaystoSuppress
InvasionandMetastasis
To understand the mechanisms by which metastasis is reg-
ulated, we have focused on identifying key signaling path-
ways that can inhibit breast cancer metastasis to the bone.
Metastasis suppressors deﬁne a class of proteins that do not
aﬀect primary tumor growth but instead regulate one or
more steps in the process leading to metastasis: invasion, in-
travasation, circulation, extravasation, and colonization of
the secondary site [16]. Raf kinase inhibitory protein (RKIP)
was initially shown to function as a metastasis suppressor in
a prostate xenograft mouse model [17]. More recently, we
haveshownthatRKIPalsosuppressesmetastaticprogression
to bone in breast tumor xenografts [18]. Furthermore, we
demonstrated that RKIP inhibits breast cancer invasion,
intravasation, and bone metastasis via a signaling pathway
involving induction of the microRNA let-7. Speciﬁcally,
inhibition of the Raf/MEK/MAP kinase cascade by RKIP
leads to inhibition of Myc activation. Myc is a transcriptional
activator of LIN28, which in turn inhibits let-7 maturation.
Consistent with the role of this signaling cascade, LIN28 has
been implicated in breast cancer progression and let-7 func-
tions as an inhibitor of breast tumor formation [19]. We also
showed that let-7 inhibits invasion in part via suppression
of the chromatin remodeling factor high mobility group AT-
hook 2 (HMGA2). HMGA2 in turn activates Snail, a tran-
scription factor that promotes the epithelial-mesenchymal
transition (EMT), a process that favors the acquisition of an
invasive phenotype. To understand how this upstream sig-
naling cascade regulates genes that are involved in the cross-
talk with the tumor microenvironment, thus aﬀecting breast
cancer metastasis to the bone, we sought to identify relevant
metastatic genes that function downstream of the RKIP/let-7
axis.
As a means of identifying signaling pathways down-
streamofakeymetastasisregulatorincancer,theRosnerand
Minn groups developed a novel interdisciplinary approach
that utilizes clinical data from breast tumors to generate
and test hypotheses [20]. The basic idea is to determine
whether a discrete set of genes are targets of inhibition by a
metastasis suppressor, in this case RKIP. If RKIP inhibits ex-
pression of these genes, then their expression levels in breast
tumors should inversely correlate with RKIP expression.
Once we identiﬁed genes that inversely correlate with RKIP
in patients’ tumors, we tested them experimentally in vitro
using breast tumor cell lines and in vivo using a xenograft
mouse model. Finally, having determined which genes
regulate metastasis in experimental breast tumor models, we
validated their clinical signiﬁcance by further bioinfomatic
analysis using independent breast tumor data.
Using this approach, we identiﬁed a number of RKIP-
regulated let-7 targets including HMGA2 and a novel target,
BTB-and-CNC homology 1 (BACH1). A leucine zipper
transcription factor, BACH1, has been linked previously to
senescenceandhemeoxidationbuthasneverbeencorrelated
to cancer progression [21]. Experimental validation using a
xenograft mouse model conﬁrmed that RKIP and let-7 sup-
press BACH1 and HMGA2 expression and showed that
BACH1 promotes invasion, intravasation, and bone metas-
tasis of breast cancer cells.
To test the hypothesis that RKIP is a potential regulator
of genes implicated in the development of bone metastasis,
we performed a similar bioinformatic analysis. We initially
determined whether RKIP expression inversely correlates to
the expression of bone metastasis signature (BMS) genes
[11]. We assembled several cohorts of primary breast tumor
expression array data and performed gene set analysis (GSA)
correlating the expression levels of the set of BMS genes to
RKIP expression. As expected, we found a negative corre-
lation between RKIP and BMS genes in two independent
gene expression data sets of 443 and 871 breast cancer
patients [20]. Thus, when RKIP is expressed, BMS genes
show low expression levels and vice versa. Having found a
signiﬁcant correlation, we experimentally tested ﬁve genes
that were previously implicated as promoting breast tumor
bonemetastasisbyregulatinginteractionsofcancercellswith
the stroma. Of these, we were able to demonstrate that RKIP
inhibits expression of MMP-1, CXCR4, and OPN thus af-
fecting the ability of metastatic cells to create an osteolytic
bone environment via crosstalk with stromal cellular and
noncellular components.
Finally, we determined experimentally the relationship
between RKIP, let-7, the two let-7 targets, HMGA2 and
BACH1, and the three BMS genes. Interestingly, knockdown
of BACH1 suppressed the BMS genes MMP1 and CXCR4
butnotOPNwhileHMGA2knockdownsuppressedCXCR4,
and OPN but not MMP1. Additionally, we could partially
reverse the eﬀects of HMGA2 and BACH1 knockdown on
invasion and metastasis by overexpressing their target BMS
genes MMP1, CXCR4 and OPN. The simultaneous overex-
pressionofthethreeBMSgenestogethershowedamorepro-
found eﬀect on the metastatic phenotype compared to the
overexpression of a single gene. These results suggest that the
coordinate regulation of genes with diﬀerent metastasis-pro-
moting functions is a prerequisite for eﬃcient metastatic
spread.4 International Journal of Breast Cancer
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Figure 1: Schematic representation of the RKIP signaling pathway and its eﬀects on metastatic progression to the bone.
Having determined which genes regulate metastasis in
experimental breast tumor models, we deﬁned a signaling
pathway signature termed the RKIP pathway metastasis sig-
nature(RPMS)thatwecouldusetofurthervalidatetheclini-
cal signiﬁcance of our ﬁndings [20]. While typical gene ex-
pression signatures do not implicate any regulatory relation-
ship between the genes in the signatures, the RPMS is based
upon experimentally validated regulatory relationships be-
tween the components of the pathway. Bioinfomatic analysis
using breast tumor data showed that the complete RPMS can
predictgreaterriskformetastasisinpatients. Bycontrast,the
individualgenesintheRPMSpathwaywereunabletopredict
metastasis-free survival. Taken together, these results high-
light the importance of evaluating both regulators of tumor
metastasis as well as genes that interact with the cellular sig-
naling environment in order to be able to predict metastatic
risk.
3.Signiﬁcance
The results described here reveal a novel regulatory mecha-
nism, controlled by the RKIP signaling pathway, that modu-
lates the dialogue between breast tumor cells and the micro-
environment and aﬀects metastatic progression to the bone
(Figure 1). Speciﬁcally, recent studies demonstrate that
BACH1 and HMGA2 are key targets for inhibition by the
RKIP signaling pathway via a let-7-dependent mechanism.
Furthermore, BACH1 and HMGA2 promote the develop-
ment of bone metastasis by inducing expression of genes
(MMP1, CXCR4, and OPN) that regulate properties of the
stromal compartment at the target organ site. Finally, since
OPN is regulated exclusively by HMGA2 and MMP1 by
BACH1, the signaling pathways downstream of RKIP exhibit
a degree of speciﬁcity. While the function of these genes has
been studied extensively in the past in the context of metas-
tasis, the regulatory mechanisms and signaling pathways that
control their expression were thus far incompletely inves-
tigated. The ability to manipulate a set of bone metastasis
genes through a common upstream regulator such as RKIP
reveals potential therapeutic targets that could have a pro-
f o u n di m p a c to np r e v e n t i o no fm e t a s t a s i si nb r e a s tc a n c e r
patients.
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